609 results for "krytan tek side effects"

Search for:

Date Range to

609 Results on GlaucomaToday.com

August 2016August 2016

Highlights of the 2016 ARVO Annual Meeting Select research findings presented this year.
By Sze H. Wong, MD, and Albert S. Khouri, MD

The Literature By Leonard K. Seibold, MD; Malik Y. Kahook, MD; and Jeffrey R. SooHoo, MD

What Is the Real IOP? Laboratory studies may help us better understand our clinical dilemmas.
By Dan Eisenberg, MD

June 2016June 2016

The Literature By Reena A. Garg, MD, and Helen Jiang, MD

Detecting and Treating Glaucoma in a Myopic Patient Without High IOP By Robert Chang, MD, and Kuldev Singh, MD, MPH

The Eyes of Africa Project Partners bring comprehensive eye care to rural Malawi.
By William Eric Sponsel, MD

Assessing Corneal Biomechanics The importance of these properties rests primarily with their effects on IOP measurement.
By Leon W. Herndon, MD

Evaluating Quality of Life in Glaucoma Understand the impact of the disease to improve care.
By Felipe A. Medeiros, MD, PhD

Do We Need Perimetry? As glaucoma advances, visual field testing provides valuable insight.
By Murray Fingeret, OD

Enhancing Visual Field Testing Techniques to increase the value and reliability of visual fields.
By Oluwatosin Smith, MD

The Role of Optic Nerve Head Imaging Past, present, and future.
By Anitra Turner, MD, and Anjali Bhorade, MD, MSCI

Optical Coherence Tomography as a Glaucoma Screening Tool Does it affect glaucoma detection in the community?
By Lisa F. Rosenberg, MD, and Casey Cahill, MD

Is There Still a Role for Optic Disc Photography? New is not necessarily better.
By George L. Spaeth, MD; Kamran Rahmatnejad, MD; and Lichuan Zeng, BSE

Fighting Side by Side By Sze H. Wong, MD

Down, But Not Out: How the AAO Has Responded to Medicare's 2016 Ophthalmology Fee Cuts Faced with cuts to ophthalmic reimbursements, the American Academy of Ophthalmology sprang into action.
By George A. Williams, MD

Industry News

April 2016April 2016

The Literature By Alex S. Huang, MD, PhD, and Alan T. Begian

What Is the Real IOP? How laboratory glaucoma studies may help us better understand this clinical dilemma.
By Nathan Radcliffe, MD

Screening the Future By Avni Shah, MD

Why I Perform Research in a Clinical Practice Participating in clinical research provides new options for my patients and growth opportunities for my practice.
By Gregory D. Parkhurst, MD

Highlights of the AGS Annual Meeting The latest research findings from the 26th annual meeting of the American Glaucoma Society, held March 3 to 6, 2016, in Fort Lauderdale, Florida.
By Geoffrey T. Emerick, MD

Rho Kinase/Norepinephrine Transporter Inhibition for the Treatment of Glaucoma and Ocular Hypertension An update on the clinical development of a new class of drugs.
By Jason Bacharach, MD

Tools of the Tube Trade By Jonathan S. Myers, MD

February 2016February 2016

The Literature By Andrew Garcia, MD, and Christopher C. Teng, MD

Addressing Poor Adherence By Larissa Habib, MD

Is the Grass Really Greener on the Other Side? The pros and cons of ophthalmology business models.
By Richard A. Lehrer, MD

Dealing With Reimbursement Cuts Two surgeons share their strategies.
By Paul F. Palmberg, MD, PhD, and Jeffrey A. Kammer, MD

Benchmarking and the Power of No Focus, not multitasking, is needed.
By Sean Rochelle

Update on Sustained-Release Drug Therapies These therapies have the potential to change the glaucoma treatment paradigm.
By Jonathan S. Myers, MD, and Scott J. Fudemberg, MD

S or C Corporation? Maximize tax deductions by using both.
By Carole C. Foos, CPA, and David B. Mandell, JD, MBA

Industry News

SIGS: a Simple Surgical Approach to Trabeculectomy By Yuri McKee, MD

December 2015December 2015

Lose the Cape By Steven D. Vold, MD, Chief Medical Editor

The Literature By Paul Lee, MD

Outflow Resistance Implications for canal-based surgery.
By Haiyan Gong, MD, PhD

Ab Interno Canaloplasty A minimally invasive and maximally effective glaucoma treatment.
By Mahmood A. Khaimi, MD

Advances in Ophthalmologic Imaging The current state of optical coherence tomography in glaucoma and the technology’s future applications.
By Scott Butikofer, MD; Kevin Pikey, DO; and Rohit Krishna, MD

The Phase 3 Pipeline Glaucoma drugs in the works.
By Douglas J. Rhee, MD, and Emily Ahadizadeh, BS

Sidebar: My Experience With a Dual-Blade Device By Leonard K. Seibold, MD

Glaucoma Research in India Although Indian ophthalmologists author many studies, the sheer volume of patients in the face of limited resources challenges most clinicians’ ability to devote much time to research.
By Subhabrata Chakrabarti, PhD, and Chandra S. Garudadri, MD

12345678910111213141516 | Next >